Notably, HER2-targeting TCBs (HER2-CD3H and HER2-CD3L) achieved higher tumor tissue concentrations than gD-targeting TCBs, highlighting the critical role of HER2 binding in driving tumor distribution of TCB. This evidence concerns the gene ERBB2 and neoplasm.